Business in Brief
No major side effects for Teva after Copaxone patent loss; Mivtach Shamir opens talks with Bright Food over possible Tnuva deal, Castro profits slump and tech shares lead TASE above 1,400 points.
Mild market reaction as Teva loses Copaxone patent
register with haaretz
Like us on Facebook and get articles directly in your news feed